FDA gains power to block food additives; manufacturers must prove safety first
H.R. 4958 — GRAS Act · Filed by Frank Pallone (D-NJ) · 5 cosponsors · Introduced Aug 12, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill removes the automatic exemption that food additives have from FDA pre-market review if they are 'generally recognized as safe' (GRAS). Instead, manufacturers must notify the FDA before using any new GRAS substance or any substance not marketed in U.S. foods before enactment, provide detailed safety data, and wait for FDA approval before marketing. The FDA must also systematically reassess the safety of at least 10 existing GRAS substances every 3 years and can revoke prior approvals if new evidence emerges. Manufacturers and petitioners pay fees to fund these reviews.
Why we flagged it
The bill's core mechanism is to eliminate a regulatory exemption and impose pre-market notification and periodic reassessment requirements on food additives. This is a straightforward expansion of FDA authority and consumer protection, not a carve-out or subsidy.
What the text implies
- The 180-day (plus optional 90-day extension) review timeline may create bottlenecks if FDA lacks resources, potentially delaying new food products and innovation, though the bill authorizes appropriations to address this.
- Manufacturers may face significant compliance costs gathering and submitting detailed safety data, which could be passed to consumers through higher food prices, particularly for smaller food companies with fewer resources.
- The reassessment requirement applies retroactively to substances already on the market and deemed GRAS before enactment, potentially destabilizing the food supply if many substances are revoked, though the bill allows FDA to correct decisions if new evidence emerges.
- The definition of 'conflict of interest' for expert reviewers is broad and may exclude qualified scientists with any financial ties to the food industry, potentially limiting the pool of available experts and slowing reviews.
- Public comment periods (60+ days) and website posting requirements increase transparency but may also invite litigation and regulatory challenges from advocacy groups, creating uncertainty for manufacturers.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
Ordinary citizens gain stronger pre-market safety oversight of food additives and periodic reassessment of existing ones, closing a regulatory loophole that has allowed substances into the food supply with minimal FDA scrutiny. The bill imposes compliance costs on manufacturers, but those costs are borne by industry, not consumers directly, and the public receives enhanced protection against unsafe additives.
Who stands to gain
- FDA (increased appropriations and fee revenue)
- Contract research organizations and toxicology labs (hired to conduct reassessments)
- Regulatory consultants and food safety compliance firms
Named in the bill
FDA (Food and Drug Administration), Federal Food, Drug, and Cosmetic Act, EPA (Environmental Protection Agency), International Agency for Research on Cancer, National Toxicology Program, Food manufacturers and additive suppliers
Where it stands
5 cosponsors: 5 Democrats.
- Aug 12, 2025 — Introduced · Congress.gov: “Introduced in House”
- Aug 12, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
12 lobbying clients named this bill on 13 disclosure filings across 3 quarters, Dec 2025 to Jun 2026. Those filings disclosed $4,465,234 in lobbying spend. A filing names 11 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 93% of bills with at least one filing.
Frank Pallone, the sponsor, reported $1,601,749 in PAC receipts in the 2026 cycle. $4,500 of that came from 2 PACs tied to these lobbying clients.
- American Beverage Association — $1,290,000 on 1 filing
- Abbott Laboratories — $1,150,000 on 1 filing
- Celanese Corporation — $460,000 on 1 filing
- Consumer Healthcare Products Association — $445,234 on 2 filings
- American Bakers Association — $380,000 on 1 filing
Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (13,123 characters) on Aug 20, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Dec 2025 to Jun 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Jul 20, 2026 · page rendered 2026-10-20.
“FDA gains power to block food additives; manufacturers must prove safety first” QuorumCivic. https://share.quorumcivic.app/bill/119/hr4958 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.